Ibrutinib Dose Reduction Did Not Affect PFS in Waldenström Macroglobulinemia
The need for dose reductions did not significantly affect progression-free survival in patients with WM treated with ibrutinib.
Waldenstrom Macroglobulinemia
Long-Term Data Show Low Risk of Second Primary Malignancy, Transformation in WM
Study shows risk of second primary malignancy or transformation to lymphoma is low.
Next-Generation Sequencing Helped Identify Pathways for Transformation of WM to DLBCL
IGHV analysis demonstrated that DLBCL tissue was clonally related to the antecedent WM clone.
BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
BeiGene released results from its phase 1 clinical trial of the investigational BTK inhibitor zanubrutinib.
Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
Carfilzomib-based regimens are well tolerated and offer a neuropathy-sparing approach in newly diagnosed MM and WM.
Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia
The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.
Ibrutinib Plus Rituximab Granted FDA Approval for Waldenström Macroglobulinemia
Rituximab plus ibrutinib is the first nonchemotherapy combination regimen approved in Waldenström macroglobulinemia.
Half-Dose R-CHOP May Be Effective, Reduce Toxicity, in Waldenström Macroglobulinemia
Due to its rarity, there is neither robust evidence nor many completed studies supporting specific treatment regimens in Waldenström macroglobulinemia.
Soluble PD-1 Ligands May Contribute to the Pathogenesis of Waldenström Macroglobulinemia
New evidence appears to support the potential utility of checkpoint inhibitors in Waldenström macroglobulinemia.
Next post in Hematologic Cancers
